| Autor: |
Manh ND; Vietnam People's Army Military Institute of Preventive Medicine (MIPM), Hanoi, Vietnam., Thanh NV; Vietnam People's Army Military Institute of Preventive Medicine (MIPM), Hanoi, Vietnam., Quang HH; Vietnam Ministry of Health Institute of Malariology, Parasitology and Entomology, Quy Nhon (IMPE-QN), Vietnam., Van NTT; Vietnam People's Army Military Institute of Preventive Medicine (MIPM), Hanoi, Vietnam., San NN; Vietnam People's Army Military Institute of Preventive Medicine (MIPM), Hanoi, Vietnam., Phong NC; Vietnam People's Army Military Institute of Preventive Medicine (MIPM), Hanoi, Vietnam., Birrell GW; Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Australia., Edstein MD; Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Australia., Edgel KA; U.S. Naval Medical Research Unit TWO (NAMRU-2), Singapore., Martin NJ; U.S. Naval Medical Research Unit TWO (NAMRU-2), Singapore., Chavchich M; Australian Defence Force Malaria and Infectious Disease Institute (ADFMIDI), Brisbane, Australia. |
| Abstrakt: |
The rise in Plasmodium falciparum resistance to dihydroartemisinin-piperaquine in Vietnam justifies the need to evaluate alternative artemisinin-based combination therapies. Between July 2018 and October 2019, a single-arm trial of pyronaridine-artesunate (Pyramax, PA) was conducted in Dak Nong province, Vietnam. PA (3-day course) was administered to adults and children infected with P. falciparum. PA was well tolerated by the participants. The proportion of patients with Day 42 PCR-corrected adequate clinical and parasitological response was 95.2% (95% confidence interval [CI], 82.3 to 98.8, n = 40/42) for treating falciparum malaria. The median parasite clearance half-life was 6.7 h (range, 2.6 to 11.9) and the median parasite clearance time was 72 h (range, 12 to 132) with 44.9% (22/49) of patients having positive blood films at 72 h. The two patients that recrudesced had comparable Day 7 blood pyronaridine concentrations (39.5 and 39.0 ng/ml) to the 40 patients who did not recrudesce (median 43.4 ng/ml, 95% CI, 35.1 to 54.9). Ring-stage and piperaquine survival assays revealed that of the 29 P. falciparum isolates collected from the patients before PA treatment, 22 (75.9%) had reduced susceptibility to artemisinins and 17 (58.6%) were resistant to piperaquine. Genotyping confirmed that 92.0% (46/50) of falciparum patients were infected with parasites bearing the Pfkelch13 C580Y mutation associated with artemisinin resistance. Of these, 56.0% (28/50) of the isolates also had multiple copies of the plasmepsin 2/3 genes responsible for piperaquine resistance. Overall, PA was effective in treating P. falciparum in the Central Highlands of Vietnam. (This study has been registered at AustralianClinicalTrials.gov.au under trial ID ACTRN12618001429246.). |
